Clinical application of thioredoxin reductase as a novel biomarker in liver cancer
Abstract Hepatic cancer is often amenable to surgery, including percutaneous ablation, trans-arterial chemoembolization. However, in metastatic cases, surgery is often not an effective option. Chemotherapy as a conventional clinical method for treatment of malignant diseases may be useful in such ca...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-03-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-85688-3 |
| _version_ | 1818425294057373696 |
|---|---|
| author | Xuping Wu Qi Wang Yousheng Lu Jinye Zhang Hanwei Yin Yongxiang Yi |
| author_facet | Xuping Wu Qi Wang Yousheng Lu Jinye Zhang Hanwei Yin Yongxiang Yi |
| author_sort | Xuping Wu |
| collection | DOAJ |
| description | Abstract Hepatic cancer is often amenable to surgery, including percutaneous ablation, trans-arterial chemoembolization. However, in metastatic cases, surgery is often not an effective option. Chemotherapy as a conventional clinical method for treatment of malignant diseases may be useful in such cases, but it is likewise not always able to slow or halt progression, therefore novel approaches for treatment of hepatic cancer are needed. Current research suggests that molecular tumor markers (TM) can play a crucial role for diagnosis and prognostic evaluation of malignancies, and TM such as AFP, CEA, CA19-9 have been reported in many malignant diseases. Thioredoxin reductase (TrxR), a type of anti-oxidant biomarker, has become a TM of significant interest. However, little is known about the above TM and TrxR activity in liver cancer. Therefore, this paper aimed to assess these TM with regards to diagnosis and and monitoring treatment efficacy in both primary and metastatic liver cancer. Our results showed TrxR had superior performance for discriminating between liver cancer patients and healthy controls than AFP, CEA, and CA19-9. TrxR also exhibited superior performance for assessing benefits of chemotherapy regardless if patients had PLC or MLC. Meanwhile, due to diagnostic efficiency of unresponsive chemotherapy patients, TrxR also showed a higher activity levels than other general markers in liver metastasis patients. Our results suggest that application of TrxR in combination with other tumor markers may maximize the efficiency of diagnosis and assessment of therapeutic efficiency, and provide new insights for the clinical application of TrxR as a candidate biomarker for liver cancer. |
| first_indexed | 2024-12-14T14:11:39Z |
| format | Article |
| id | doaj.art-ea2342db5ee242668d9b3e5263a5e4c3 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-14T14:11:39Z |
| publishDate | 2021-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-ea2342db5ee242668d9b3e5263a5e4c32022-12-21T22:58:18ZengNature PortfolioScientific Reports2045-23222021-03-0111111210.1038/s41598-021-85688-3Clinical application of thioredoxin reductase as a novel biomarker in liver cancerXuping Wu0Qi Wang1Yousheng Lu2Jinye Zhang3Hanwei Yin4Yongxiang Yi5The Second Hospital of Nanjing, Nanjing University of Chinese MedicineKeaise Center for Clinical LaboratoryJiangsu Provincial Cancer Hospital and Jiangsu Provincial Cancer Institute, Medical Department of Cancer Hospital Affiliated to Nanjing Medical UniversityNantong Tumor HospitalKeaise Center for Clinical LaboratoryThe Second Hospital of Nanjing, Nanjing University of Chinese MedicineAbstract Hepatic cancer is often amenable to surgery, including percutaneous ablation, trans-arterial chemoembolization. However, in metastatic cases, surgery is often not an effective option. Chemotherapy as a conventional clinical method for treatment of malignant diseases may be useful in such cases, but it is likewise not always able to slow or halt progression, therefore novel approaches for treatment of hepatic cancer are needed. Current research suggests that molecular tumor markers (TM) can play a crucial role for diagnosis and prognostic evaluation of malignancies, and TM such as AFP, CEA, CA19-9 have been reported in many malignant diseases. Thioredoxin reductase (TrxR), a type of anti-oxidant biomarker, has become a TM of significant interest. However, little is known about the above TM and TrxR activity in liver cancer. Therefore, this paper aimed to assess these TM with regards to diagnosis and and monitoring treatment efficacy in both primary and metastatic liver cancer. Our results showed TrxR had superior performance for discriminating between liver cancer patients and healthy controls than AFP, CEA, and CA19-9. TrxR also exhibited superior performance for assessing benefits of chemotherapy regardless if patients had PLC or MLC. Meanwhile, due to diagnostic efficiency of unresponsive chemotherapy patients, TrxR also showed a higher activity levels than other general markers in liver metastasis patients. Our results suggest that application of TrxR in combination with other tumor markers may maximize the efficiency of diagnosis and assessment of therapeutic efficiency, and provide new insights for the clinical application of TrxR as a candidate biomarker for liver cancer.https://doi.org/10.1038/s41598-021-85688-3 |
| spellingShingle | Xuping Wu Qi Wang Yousheng Lu Jinye Zhang Hanwei Yin Yongxiang Yi Clinical application of thioredoxin reductase as a novel biomarker in liver cancer Scientific Reports |
| title | Clinical application of thioredoxin reductase as a novel biomarker in liver cancer |
| title_full | Clinical application of thioredoxin reductase as a novel biomarker in liver cancer |
| title_fullStr | Clinical application of thioredoxin reductase as a novel biomarker in liver cancer |
| title_full_unstemmed | Clinical application of thioredoxin reductase as a novel biomarker in liver cancer |
| title_short | Clinical application of thioredoxin reductase as a novel biomarker in liver cancer |
| title_sort | clinical application of thioredoxin reductase as a novel biomarker in liver cancer |
| url | https://doi.org/10.1038/s41598-021-85688-3 |
| work_keys_str_mv | AT xupingwu clinicalapplicationofthioredoxinreductaseasanovelbiomarkerinlivercancer AT qiwang clinicalapplicationofthioredoxinreductaseasanovelbiomarkerinlivercancer AT youshenglu clinicalapplicationofthioredoxinreductaseasanovelbiomarkerinlivercancer AT jinyezhang clinicalapplicationofthioredoxinreductaseasanovelbiomarkerinlivercancer AT hanweiyin clinicalapplicationofthioredoxinreductaseasanovelbiomarkerinlivercancer AT yongxiangyi clinicalapplicationofthioredoxinreductaseasanovelbiomarkerinlivercancer |